2021
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
Weishaar K, Wright Z, Rosenberg M, Post G, McDaniel J, Clifford C, Phillips B, Bergman P, Randall E, Avery A, Thamm D, Hull A, Gust C, Donoghue A. Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma. Journal Of Veterinary Internal Medicine 2021, 36: 215-226. PMID: 34952995, PMCID: PMC8783351, DOI: 10.1111/jvim.16341.Peer-Reviewed Original ResearchConceptsBest overall response ratePlacebo-treated dogsProgression-free survivalOverall response rateAdverse eventsResponse rateMedian progression-free survivalCommon adverse eventsPlacebo-controlled studySerious adverse eventsNovel chemotherapy agentsClient-owned dogsTreatment of lymphomaRAB groupSignificant antitumor efficacyStudy endpointMulticentric lymphomaTreatment completionChemotherapy agentsPercent progressionSafety dataLast treatmentClinical importanceLymphomaRabacfosadine
2012
Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision
Dank G, Rassnick K, Sokolovsky Y, Garrett L, Post G, Kitchell B, Sellon R, Kleiter M, Northrup N, Segev G. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Veterinary And Comparative Oncology 2012, 12: 78-84. PMID: 22737988, DOI: 10.1111/j.1476-5829.2012.00338.x.Peer-Reviewed Original ResearchConceptsMalignant melanomaOverall median progression-free survivalMedian progression-free survivalProgression-free survival eventsAdjuvant carboplatin chemotherapyCommon oral malignancyMalignant oral melanomasMedian overall survivalProgression-free survivalOral malignant melanomaTreatment of dogsNumber of dosesCanine malignant melanomaCause of deathAdjuvant carboplatinCarboplatin chemotherapyMedian dosageOverall survivalSurgical resectionSystemic therapyLocal recurrenceOral malignanciesSurgical excisionRetrospective studyOral melanoma